Figures & data
Figure 1 Receiver operating characteristic curve illustrating that blood eosinophils are a marker of sputum eosinophil-associated exacerbations.
Abbreviations: IL, interleukin; CCL, chemokine ligand; TNF, tumor necrosis factor; VCAM, vascular cell adhesion molecule.
![Figure 1 Receiver operating characteristic curve illustrating that blood eosinophils are a marker of sputum eosinophil-associated exacerbations.](/cms/asset/af155811-8201-4eaa-8829-81fee12977f7/dcop_a_85978_f0001_b.jpg)
Table 1 Symptomatic components of an exacerbation, evaluated using the EXAcerbation of COPD Tool (EXACT)Citation17
Figure 2 EXAcerbations of COPD Tool (EXACT) scores for reported (identified by health care resource utilization and by EXACT) and unreported (identified by EXACT only) exacerbations.Citation1
![Figure 2 EXAcerbations of COPD Tool (EXACT) scores for reported (identified by health care resource utilization and by EXACT) and unreported (identified by EXACT only) exacerbations.Citation1](/cms/asset/900dabf7-a706-4cbd-b3cf-b1fe1fe9c9fd/dcop_a_85978_f0002_b.jpg)
Figure 3 Natural history of COPD in a cohort of 73,106 patients after first hospitalization for a severe exacerbation, showing (A) rate of next severe exacerbation and (B) rate of next severe exacerbation or death per 10,000 patients per day.Citation3
![Figure 3 Natural history of COPD in a cohort of 73,106 patients after first hospitalization for a severe exacerbation, showing (A) rate of next severe exacerbation and (B) rate of next severe exacerbation or death per 10,000 patients per day.Citation3](/cms/asset/1780bdd7-c563-48da-8e7e-fb0de8b14add/dcop_a_85978_f0003_b.jpg)
Figure 4 Annual rate of exacerbations, systemic corticosteroid prescriptions, and hospitalizations in a randomized, placebo-controlled trial of combination therapy with a long-acting β-agonist and inhaled corticosteroid in patients with COPD.
![Figure 4 Annual rate of exacerbations, systemic corticosteroid prescriptions, and hospitalizations in a randomized, placebo-controlled trial of combination therapy with a long-acting β-agonist and inhaled corticosteroid in patients with COPD.](/cms/asset/18e8adc8-6f2f-4455-8f12-284d67ccbaf7/dcop_a_85978_f0004_b.jpg)